Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avalyn PharmaAVLN -1.01%11 Median PS Value is $0.00 as of Aug. 04, 2026. GuruFocus rates AVLN with a GF Score™ of 11/100. Among 278 Biotechnology companies, Avalyn Pharma ranks worse than 359711.87% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
As of today (2026-08-04), Avalyn Pharma's share price is $28.50. Avalyn Pharma's Median PS Value is $0.00. Therefore, Avalyn Pharma's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Avalyn Pharma's Median PS Value or its related term are showing as below:
AVLN's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.61 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Avalyn Pharma (NAS:AVLN) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Avalyn Pharma's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
28.50
/
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma Median PS Value Related Terms
Avalyn Pharma Median PS Value Historical Data
* Premium members only.
The historical data trend for Avalyn Pharma's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma Median PS Value Chart
Avalyn Pharma Annual Data
Trend
Dec24
Dec25
Median PS Value
0.00
0.00
Avalyn Pharma Semi-Annual Data
Dec24
Dec25
Median PS Value
0.00
0.00
AVLN vs TRAX, IMTX, ARDX: Median PS Value Comparison
For the Biotechnology subindustry, Avalyn Pharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avalyn Pharma Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avalyn Pharma's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Avalyn Pharma's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is .
For company reported annually, GuruFocus uses latest annual data as the TTM data. Avalyn Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma (AVLN) has a Median PS Value of $0.00 as of Aug. 04, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Avalyn Pharma and its competitors. According to the industry distribution chart, Avalyn Pharma ranks #999999 out of 278 companies in the Biotechnology industry.
Is Avalyn Pharma's Median PS Value too high?
Avalyn Pharma's current Median PS Value is $0.00. Based on the distribution chart, Avalyn Pharma ranks #999999 out of 278 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avalyn Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's Median PS Value compare to TRAX and IMTX?
According to the Biotechnology industry distribution chart, Avalyn Pharma ranks #999999 out of 278 companies for Median PS Value. This places Avalyn Pharma in the lower half of its industry. The industry median Median PS Value is 0.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.61, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Avalyn Pharma and its competitors. For the Biotechnology industry, the median Median PS Value is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avalyn Pharma's current Median PS Value is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current Median PS Value of $0.00. The current Median PS Value is $0.00. Avalyn Pharma's overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current Median PS Value is $0.00 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
11GF Score
Get the complete analysis for AVLN
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVLN has been successfully added to your 
